{"recordsFiltered":50008,"recordsTotal":50008,"next":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=days_late&start=47700","previous":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=days_late&start=47100","results":[{"registry_id":"NCT07169617","publication_url":"https://clinicaltrials.gov/study/NCT07169617","title":"Evaluating the Feasibility of a Survivin Peptide Vaccine (SurVaxM) as an Interception Agent in Patients at High Risk for Lung Cancer","has_exemption":false,"start_date":"2026-07-01","completion_date":"2029-03-30","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07768371","publication_url":"https://clinicaltrials.gov/study/NCT07768371","title":"A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy and Safety of Remibrutinib (LOU064) in Adult and Adolescent Participants With IgE-mediated Food Allergy","has_exemption":false,"start_date":"2026-09-11","completion_date":"2029-03-30","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07775287","publication_url":"https://clinicaltrials.gov/study/NCT07775287","title":"A Randomized, Open-label, Phase 3 Trial of Petosemtamab + FOLFIRI/mFOLFOX6 Versus Cetuximab or Bevacizumab + FOLFIRI/mFOLFOX6 as Second-line Treatment in Participants With RAS and BRAF Wild-type, Recurrent, Unresectable or Metastatic Colorectal Cancer","has_exemption":false,"start_date":"2026-09-15","completion_date":"2029-03-30","has_results":false,"results_due":false,"sponsor_name":"Genmab","sponsor_slug":"genmab","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07653243","publication_url":"https://clinicaltrials.gov/study/NCT07653243","title":"A Randomized, Sham-Controlled Trial of Home-Based Lower-Extremity Heat Therapy in Adults With Peripheral Artery Disease","has_exemption":false,"start_date":"2027-01-01","completion_date":"2029-03-30","has_results":false,"results_due":false,"sponsor_name":"Aquilo Sports, LLC","sponsor_slug":"aquilo-sports-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT00185744","publication_url":"https://clinicaltrials.gov/study/NCT00185744","title":"Accelerated Partial Breast Irradiation Following Lumpectomy for Breast Cancer","has_exemption":false,"start_date":"2002-09-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02716246","publication_url":"https://clinicaltrials.gov/study/NCT02716246","title":"Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA","has_exemption":false,"start_date":"2016-04-25","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Ultragenyx Pharmaceutical Inc","sponsor_slug":"ultragenyx-pharmaceutical-inc","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03153475","publication_url":"https://clinicaltrials.gov/study/NCT03153475","title":"Multi-Center Clinical Evaluation of the ATTUNE® Revision System in Revision Total Knee Arthroplasty","has_exemption":false,"start_date":"2017-05-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"DePuy Orthopaedics","sponsor_slug":"depuy-orthopaedics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03167203","publication_url":"https://clinicaltrials.gov/study/NCT03167203","title":"A Safety Surveillance Study of Events of Special Interest Occurring in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy","has_exemption":false,"start_date":"2018-01-08","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Astellas Institute for Regenerative Medicine","sponsor_slug":"astellas-institute-for-regenerative-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03493425","publication_url":"https://clinicaltrials.gov/study/NCT03493425","title":"Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)","has_exemption":false,"start_date":"2019-03-12","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"ECOG-ACRIN Cancer Research Group","sponsor_slug":"ecog-acrin-cancer-research-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04740476","publication_url":"https://clinicaltrials.gov/study/NCT04740476","title":"An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001","has_exemption":false,"start_date":"2021-01-20","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Stoke Therapeutics, Inc","sponsor_slug":"stoke-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04786223","publication_url":"https://clinicaltrials.gov/study/NCT04786223","title":"Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias","has_exemption":false,"start_date":"2021-03-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Val Lowe","sponsor_slug":"val-lowe","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04884815","publication_url":"https://clinicaltrials.gov/study/NCT04884815","title":"An Operationally Seamless Phase 1/2/3 Study Consisting of a Safety and Dose-finding Phase 1/2 and Randomized, Open-label, Active-controlled Phase 3 to Evaluate UX701 AAV Gene Therapy in Adults With Wilson Disease","has_exemption":false,"start_date":"2021-09-27","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Ultragenyx Pharmaceutical Inc","sponsor_slug":"ultragenyx-pharmaceutical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05127226","publication_url":"https://clinicaltrials.gov/study/NCT05127226","title":"HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome","has_exemption":false,"start_date":"2021-12-22","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Ionis Pharmaceuticals, Inc.","sponsor_slug":"ionis-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04831580","publication_url":"https://clinicaltrials.gov/study/NCT04831580","title":"A Randomized Controlled Trial of Robotic Versus Open Surgery for Early Stage Cervical Cancer (ROCC)","has_exemption":false,"start_date":"2022-03-22","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"GOG Foundation","sponsor_slug":"gog-foundation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05595473","publication_url":"https://clinicaltrials.gov/study/NCT05595473","title":"A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability and Efficacy of RZ-001 in Combination with Valganciclovir in Subjects with Hepatocellular Carcinoma","has_exemption":false,"start_date":"2022-07-29","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Rznomics, Inc.","sponsor_slug":"rznomics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05604131","publication_url":"https://clinicaltrials.gov/study/NCT05604131","title":"Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients","has_exemption":false,"start_date":"2022-11-08","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Rohan Dharmakumar","sponsor_slug":"rohan-dharmakumar","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05619146","publication_url":"https://clinicaltrials.gov/study/NCT05619146","title":"Upper and Lower Extremity Cycling in Incomplete Spinal Cord Injury Individuals to Promote Limb Recovery","has_exemption":false,"start_date":"2023-01-23","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Shirley Ryan AbilityLab","sponsor_slug":"shirley-ryan-abilitylab","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05721755","publication_url":"https://clinicaltrials.gov/study/NCT05721755","title":"Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma","has_exemption":false,"start_date":"2023-06-08","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"ECOG-ACRIN Cancer Research Group","sponsor_slug":"ecog-acrin-cancer-research-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05608408","publication_url":"https://clinicaltrials.gov/study/NCT05608408","title":"Network Neuro-modulation for Mesial Temporal Lobe Epilepsy","has_exemption":false,"start_date":"2023-11-16","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Nitin Tandon","sponsor_slug":"nitin-tandon","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05172973","publication_url":"https://clinicaltrials.gov/study/NCT05172973","title":"Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves","has_exemption":false,"start_date":"2023-11-22","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Edwards Lifesciences","sponsor_slug":"edwards-lifesciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06053567","publication_url":"https://clinicaltrials.gov/study/NCT06053567","title":"Efficacy and Implementation of Exercise-based Smoking Cessation Treatment for Adults With High Anxiety Sensitivity.","has_exemption":false,"start_date":"2023-12-27","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Jasper A. Smits","sponsor_slug":"jasper-a-smits","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06305286","publication_url":"https://clinicaltrials.gov/study/NCT06305286","title":"A Pilot Study Assessing the Safety of Using a Monoclonal Antibody Against Cluster of Differentiation 40 (CD40) Ligand to Achieve a Calcineurin Inhibitor-free Immunosuppression Regimen in Patients With Type 1 Diabetes Mellitus (T1D) and Problematic Hypoglycemia Undergoing Islet Cell Transplantation","has_exemption":false,"start_date":"2024-03-04","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06292013","publication_url":"https://clinicaltrials.gov/study/NCT06292013","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)","has_exemption":false,"start_date":"2024-03-05","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06350318","publication_url":"https://clinicaltrials.gov/study/NCT06350318","title":"A Phase 2 Open-Label, Multicenter Study of Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas","has_exemption":false,"start_date":"2024-04-19","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","sponsor_slug":"h-lee-moffitt-cancer-center-and-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05977400","publication_url":"https://clinicaltrials.gov/study/NCT05977400","title":"NICU Antibiotics and Outcomes Follow-Up Study","has_exemption":false,"start_date":"2024-04-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Sharp HealthCare","sponsor_slug":"sharp-healthcare","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06319248","publication_url":"https://clinicaltrials.gov/study/NCT06319248","title":"MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial","has_exemption":false,"start_date":"2024-05-14","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06395103","publication_url":"https://clinicaltrials.gov/study/NCT06395103","title":"LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors","has_exemption":false,"start_date":"2024-08-16","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06102525","publication_url":"https://clinicaltrials.gov/study/NCT06102525","title":"A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination With Valganciclovir in Subjects With Glioblastoma","has_exemption":false,"start_date":"2024-10-08","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Rznomics, Inc.","sponsor_slug":"rznomics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06798558","publication_url":"https://clinicaltrials.gov/study/NCT06798558","title":"Phase II Study of Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy","has_exemption":false,"start_date":"2025-03-05","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Hackensack Meridian Health","sponsor_slug":"hackensack-meridian-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06542705","publication_url":"https://clinicaltrials.gov/study/NCT06542705","title":"Effect of Internal Brace on Outcomes Following ACL Reconstruction With Bone Patellar Bone (BTB) Autograft: A Randomized Controlled Trial","has_exemption":false,"start_date":"2025-03-17","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06647953","publication_url":"https://clinicaltrials.gov/study/NCT06647953","title":"Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)","has_exemption":false,"start_date":"2025-03-21","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06880770","publication_url":"https://clinicaltrials.gov/study/NCT06880770","title":"Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)","has_exemption":false,"start_date":"2025-04-24","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Arrowhead Pharmaceuticals","sponsor_slug":"arrowhead-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06682793","publication_url":"https://clinicaltrials.gov/study/NCT06682793","title":"A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","has_exemption":false,"start_date":"2025-05-22","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"A2 Biotherapeutics Inc.","sponsor_slug":"a2-biotherapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06839235","publication_url":"https://clinicaltrials.gov/study/NCT06839235","title":"A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)","has_exemption":false,"start_date":"2025-06-16","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Arbor Biotechnologies","sponsor_slug":"arbor-biotechnologies","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06757634","publication_url":"https://clinicaltrials.gov/study/NCT06757634","title":"VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib With Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer","has_exemption":false,"start_date":"2025-07-24","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Celcuity, Inc.","sponsor_slug":"celcuity-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07098988","publication_url":"https://clinicaltrials.gov/study/NCT07098988","title":"A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)","has_exemption":false,"start_date":"2025-08-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"CatalYm GmbH","sponsor_slug":"catalym-gmbh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07145736","publication_url":"https://clinicaltrials.gov/study/NCT07145736","title":"Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases: A Cluster-randomised Trial","has_exemption":false,"start_date":"2025-08-04","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Kirby Institute","sponsor_slug":"kirby-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07016698","publication_url":"https://clinicaltrials.gov/study/NCT07016698","title":"A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)","has_exemption":false,"start_date":"2025-09-29","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"C. R. Bard","sponsor_slug":"c-r-bard","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07132918","publication_url":"https://clinicaltrials.gov/study/NCT07132918","title":"The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers","has_exemption":false,"start_date":"2025-10-08","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218783","publication_url":"https://clinicaltrials.gov/study/NCT07218783","title":"A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,","has_exemption":false,"start_date":"2025-10-15","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"SpyGlass Pharma, Inc.","sponsor_slug":"spyglass-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07135050","publication_url":"https://clinicaltrials.gov/study/NCT07135050","title":"Phase 1/2 First-in-Human Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome","has_exemption":false,"start_date":"2025-12-19","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Mahzi Therapeutics","sponsor_slug":"mahzi-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07209332","publication_url":"https://clinicaltrials.gov/study/NCT07209332","title":"An Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, Pharmacokinetics, and Efficacy of WVE-N531 in Patients With Duchenne Muscular Dystrophy Who Participated in Another Study of WVE-N531","has_exemption":false,"start_date":"2025-12-28","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Wave Life Sciences USA, Inc.","sponsor_slug":"wave-life-sciences-usa-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07262619","publication_url":"https://clinicaltrials.gov/study/NCT07262619","title":"A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors","has_exemption":false,"start_date":"2026-01-20","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Eikon Therapeutics","sponsor_slug":"eikon-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06155682","publication_url":"https://clinicaltrials.gov/study/NCT06155682","title":"Cognitive and Neural Correlates of TMS Motor Intracortical Inhibition in Schizophrenia","has_exemption":false,"start_date":"2026-02-02","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Maryland, Baltimore","sponsor_slug":"university-of-maryland-baltimore","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07450859","publication_url":"https://clinicaltrials.gov/study/NCT07450859","title":"A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","has_exemption":false,"start_date":"2026-03-05","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"BicycleTx Limited","sponsor_slug":"bicycletx-limited","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07436689","publication_url":"https://clinicaltrials.gov/study/NCT07436689","title":"A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)","has_exemption":false,"start_date":"2026-03-13","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Tenax Therapeutics, Inc.","sponsor_slug":"tenax-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07459660","publication_url":"https://clinicaltrials.gov/study/NCT07459660","title":"An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis","has_exemption":false,"start_date":"2026-03-25","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"MapLight Therapeutics","sponsor_slug":"maplight-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07485738","publication_url":"https://clinicaltrials.gov/study/NCT07485738","title":"Surgical Measurement for Accurate Revascularization Using Transit-time FLOW (SMARTFLOW):Patency","has_exemption":false,"start_date":"2026-03-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Weill Medical College of Cornell University","sponsor_slug":"weill-medical-college-of-cornell-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06240455","publication_url":"https://clinicaltrials.gov/study/NCT06240455","title":"A Double-blind, Placebo-controlled, Phase 2 Dose-range Study to Assess the Efficacy and Safety of WP1302 in Preventing Disease Relapse Following Methimazole Withdrawal in Subjects With Graves' Disease","has_exemption":false,"start_date":"2026-03-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Worg Biotherapeutics Inc.","sponsor_slug":"worg-biotherapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06782542","publication_url":"https://clinicaltrials.gov/study/NCT06782542","title":"Single-Arm Phase 2 Study of Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Who Are Eligible for Intensive Induction Chemotherapy","has_exemption":false,"start_date":"2026-03-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Justin Watts, MD","sponsor_slug":"justin-watts-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07439653","publication_url":"https://clinicaltrials.gov/study/NCT07439653","title":"A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","has_exemption":false,"start_date":"2026-03-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"TORL Biotherapeutics, LLC","sponsor_slug":"torl-biotherapeutics-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07227207","publication_url":"https://clinicaltrials.gov/study/NCT07227207","title":"A Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose Expansion, and Single Repeat Dose Study of TSRA-196 in Adults With the PiZZ Genotype Who Have Lung and/or Liver Disease Associated With Severe Alpha-1 Antitrypsin Deficiency","has_exemption":false,"start_date":"2026-04-21","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Tessera Therapeutics, Inc.","sponsor_slug":"tessera-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07288437","publication_url":"https://clinicaltrials.gov/study/NCT07288437","title":"Adaptive Deep Brain Stimulation Targeting the Dentate Nucleus to Treat Spinocerebellar Ataxia","has_exemption":false,"start_date":"2026-04-27","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07547878","publication_url":"https://clinicaltrials.gov/study/NCT07547878","title":"A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD","has_exemption":false,"start_date":"2026-04-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Baylor Research Institute","sponsor_slug":"baylor-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06844383","publication_url":"https://clinicaltrials.gov/study/NCT06844383","title":"A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate","has_exemption":false,"start_date":"2026-05-05","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Prostate Cancer Clinical Trials Consortium","sponsor_slug":"prostate-cancer-clinical-trials-consortium","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07514338","publication_url":"https://clinicaltrials.gov/study/NCT07514338","title":"An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of KL1333 (Napazimone) in Patients With Primary Mitochondrial Disease","has_exemption":false,"start_date":"2026-06-09","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Pharming Technologies B.V.","sponsor_slug":"pharming-technologies-bv","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07224763","publication_url":"https://clinicaltrials.gov/study/NCT07224763","title":"EXTEND: A Prospective Study to Evaluate the Safety and Efficacy of GGTA1 KO Thymokidney XenoTransplantation in Patients With End-stage Renal Disease (ESRD)","has_exemption":false,"start_date":"2026-06-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"United Therapeutics","sponsor_slug":"united-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07605429","publication_url":"https://clinicaltrials.gov/study/NCT07605429","title":"A Randomized, Multi-center, Double-blind, Sham-controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered Rugonersen in Pediatric and Adult Participants With Angelman Syndrome","has_exemption":false,"start_date":"2026-06-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"OHB Pediatrics Ltd.","sponsor_slug":"ohb-pediatrics-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07494084","publication_url":"https://clinicaltrials.gov/study/NCT07494084","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","has_exemption":false,"start_date":"2026-07-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Washington State University","sponsor_slug":"washington-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07683000","publication_url":"https://clinicaltrials.gov/study/NCT07683000","title":"A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens","has_exemption":false,"start_date":"2026-07-14","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Gilead Sciences","sponsor_slug":"gilead-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07682961","publication_url":"https://clinicaltrials.gov/study/NCT07682961","title":"A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy","has_exemption":false,"start_date":"2026-07-14","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Gilead Sciences","sponsor_slug":"gilead-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218354","publication_url":"https://clinicaltrials.gov/study/NCT07218354","title":"CSP #2041 - Cessation or Reduction of Alcohol Consumption in VEterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder (CRAVE)","has_exemption":false,"start_date":"2026-07-28","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07639606","publication_url":"https://clinicaltrials.gov/study/NCT07639606","title":"Mobile Cognitive Behavioral Therapy in Early Stroke Recovery","has_exemption":false,"start_date":"2026-07-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Weill Medical College of Cornell University","sponsor_slug":"weill-medical-college-of-cornell-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07596914","publication_url":"https://clinicaltrials.gov/study/NCT07596914","title":"Assessing Multi-site Feasibility of an Integrated Whole-body Hyperthermia and Behavioral Intervention for Major Depressive Disorder: The MULTIBED Study","has_exemption":false,"start_date":"2026-08-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07740941","publication_url":"https://clinicaltrials.gov/study/NCT07740941","title":"NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB- IV (M1a) Melanoma","has_exemption":false,"start_date":"2026-08-05","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07078838","publication_url":"https://clinicaltrials.gov/study/NCT07078838","title":"A Randomized, Window of Opportunity Trial of Tirzepatide in Women With Obesity and a Diagnosis of Endometrial Intra-epithelial Neoplasia (EIN) or Grade 1 Endometrial Cancer","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07413744","publication_url":"https://clinicaltrials.gov/study/NCT07413744","title":"Probiotic Supplementation Safety and Feasibility Study in Preclinical Alzheimer's Disease","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07734636","publication_url":"https://clinicaltrials.gov/study/NCT07734636","title":"A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06855043","publication_url":"https://clinicaltrials.gov/study/NCT06855043","title":"Pilot Randomized Controlled Trial of Late Surfactant Therapy With Budesonide for Prevention of Bronchopulmonary Dysplasia","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Wisconsin, Madison","sponsor_slug":"university-of-wisconsin-madison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07517133","publication_url":"https://clinicaltrials.gov/study/NCT07517133","title":"A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non-Transfusion-Dependent Thalassemia","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Agios Pharmaceuticals, Inc.","sponsor_slug":"agios-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07696975","publication_url":"https://clinicaltrials.gov/study/NCT07696975","title":"RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"V-Wave Ltd","sponsor_slug":"v-wave-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07698613","publication_url":"https://clinicaltrials.gov/study/NCT07698613","title":"BrUOG 438: EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Brown University","sponsor_slug":"brown-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07777848","publication_url":"https://clinicaltrials.gov/study/NCT07777848","title":"A Randomized, Controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of RAG-01 Monotherapy and RAG-01 in Combination With Chemotherapy in Intermediate/High-risk Patients With Non-muscle Invasive Bladder Cancer (NMIBC).","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Ractigen Therapeutics.","sponsor_slug":"ractigen-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07060417","publication_url":"https://clinicaltrials.gov/study/NCT07060417","title":"The Effects of SGLT2 Inhibition on Vascular Health and Physical Function in Veterans With CKD","has_exemption":false,"start_date":"2026-10-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07104318","publication_url":"https://clinicaltrials.gov/study/NCT07104318","title":"Randomized Clinical Trial of Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans: \"VA Eradicate HP\"","has_exemption":false,"start_date":"2026-10-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07110233","publication_url":"https://clinicaltrials.gov/study/NCT07110233","title":"Prospective Phase 2 Trial of Yttrium-90 Radiation Segmentectomy for Unresectable Hepatocellular Carcinoma","has_exemption":false,"start_date":"2026-10-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07672782","publication_url":"https://clinicaltrials.gov/study/NCT07672782","title":"Phase II Study Tisotumab Vedotin in Metastatic or Recurrent Squamous Cell Carcinoma of the Vulva","has_exemption":false,"start_date":"2026-11-30","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"GOG Foundation","sponsor_slug":"gog-foundation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07572123","publication_url":"https://clinicaltrials.gov/study/NCT07572123","title":"A Two Cohort Randomized Study for Patients With High Risk (Phase II) and Standard Risk (Phase III) Classical Hodgkin Lymphoma in First Relapse","has_exemption":false,"start_date":"2026-12-04","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06167213","publication_url":"https://clinicaltrials.gov/study/NCT06167213","title":"Safety and Effectiveness of Balloon-Expandable Bioprosthetic SAPIEN X4 Transcatheter Heart Valve - Mitral","has_exemption":false,"start_date":"2027-01-31","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"Edwards Lifesciences","sponsor_slug":"edwards-lifesciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07634835","publication_url":"https://clinicaltrials.gov/study/NCT07634835","title":"Transcranial Magnetic Stimulation for Adolescents and Young Adults With Cannabis Use Disorder","has_exemption":false,"start_date":"2027-03-01","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07463807","publication_url":"https://clinicaltrials.gov/study/NCT07463807","title":"Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) Versus Carfilzomib/Pomalidomide/Dexamethasone (KPd) in Early Relapse of Multiple Myeloma","has_exemption":false,"start_date":"2027-04-12","completion_date":"2029-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04682158","publication_url":"https://clinicaltrials.gov/study/NCT04682158","title":"Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma A Phase II Study","has_exemption":false,"start_date":"2021-04-01","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"Roswell Park Cancer Institute","sponsor_slug":"roswell-park-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06499805","publication_url":"https://clinicaltrials.gov/study/NCT06499805","title":"Barriers and Facilitators to OTC Hearing Aids Success","has_exemption":false,"start_date":"2025-03-15","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"Yu-Hsiang Wu","sponsor_slug":"yu-hsiang-wu","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06828991","publication_url":"https://clinicaltrials.gov/study/NCT06828991","title":"ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL","has_exemption":false,"start_date":"2025-09-04","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"Danielle Wallace","sponsor_slug":"danielle-wallace","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06834217","publication_url":"https://clinicaltrials.gov/study/NCT06834217","title":"Characterization and Modulation of Functional Connectivity and Fear Extinction Abnormalities in Obsessive-Compulsive Disorder","has_exemption":false,"start_date":"2025-09-12","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06574009","publication_url":"https://clinicaltrials.gov/study/NCT06574009","title":"Better Options for Chronic Cancer Pain: a SMART Study","has_exemption":false,"start_date":"2025-10-07","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06743113","publication_url":"https://clinicaltrials.gov/study/NCT06743113","title":"A Multi-Center, Randomized, Controlled, Cross-Over Study to Evaluate the Effectiveness of Hypoxic Red Blood Cells Processed With the Hemanext ONE® System Versus Conventional Red Blood Cells in Patients With Transfusion Dependent Sickle Cell Anemia","has_exemption":false,"start_date":"2026-09-01","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"Hemanext","sponsor_slug":"hemanext","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02199015","publication_url":"https://clinicaltrials.gov/study/NCT02199015","title":"Lateral Cord Electrical Stimulation Can Improve Spasticity in Chronic Spastic Cerebral Palsy","has_exemption":false,"start_date":"2027-06-01","completion_date":"2029-04-01","has_results":false,"results_due":false,"sponsor_name":"Juan Carlos M. Andreani MD","sponsor_slug":"juan-carlos-m-andreani-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05295290","publication_url":"https://clinicaltrials.gov/study/NCT05295290","title":"LOW INTERVENTIONAL COHORT STUDY OF MYOCARDITIS/PERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AGE","has_exemption":false,"start_date":"2022-11-21","completion_date":"2029-04-02","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07644039","publication_url":"https://clinicaltrials.gov/study/NCT07644039","title":"A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants Who Were Previously Treated for Advanced Malignancies","has_exemption":false,"start_date":"2026-05-21","completion_date":"2029-04-02","has_results":false,"results_due":false,"sponsor_name":"PharmaMar","sponsor_slug":"pharmamar","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07169734","publication_url":"https://clinicaltrials.gov/study/NCT07169734","title":"A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","has_exemption":false,"start_date":"2025-08-26","completion_date":"2029-04-05","has_results":false,"results_due":false,"sponsor_name":"Alentis Therapeutics AG","sponsor_slug":"alentis-therapeutics-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07628049","publication_url":"https://clinicaltrials.gov/study/NCT07628049","title":"A Phase 1/2, Randomized, Controlled, Observer-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of GSK Biologicals' Investigational Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) Combination and Investigational hMPV Vaccines When Administered Intramuscularly According to a Single Dose Schedule in Younger Adults ≥18 to ≤49 Years and Older Adults Aged ≥60 to ≤80 Years","has_exemption":false,"start_date":"2026-06-05","completion_date":"2029-04-05","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07582172","publication_url":"https://clinicaltrials.gov/study/NCT07582172","title":"Phase 2 Trial of Total Marrow and Lymphoid Irradiation (TMLI) as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplantation (PBSC-HCT) From a Match Donor With Fludarabine and Melphalan in Older Patients With Refractory Acute Myeloid Leukemia and MDS","has_exemption":false,"start_date":"2027-04-05","completion_date":"2029-04-05","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07098338","publication_url":"https://clinicaltrials.gov/study/NCT07098338","title":"An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)","has_exemption":false,"start_date":"2025-08-07","completion_date":"2029-04-06","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05335928","publication_url":"https://clinicaltrials.gov/study/NCT05335928","title":"AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis","has_exemption":false,"start_date":"2022-07-02","completion_date":"2029-04-09","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07504588","publication_url":"https://clinicaltrials.gov/study/NCT07504588","title":"A Randomized Phase II Trial of Sacituzumab Govitecan (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy","has_exemption":false,"start_date":"2026-09-10","completion_date":"2029-04-12","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07215325","publication_url":"https://clinicaltrials.gov/study/NCT07215325","title":"The Effects of Doxycycline on Inflammation and the Microbiome: 'Flipping the Script' on STI PEP","has_exemption":false,"start_date":"2025-10-13","completion_date":"2029-04-13","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07354100","publication_url":"https://clinicaltrials.gov/study/NCT07354100","title":"Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)","has_exemption":false,"start_date":"2026-12-15","completion_date":"2029-04-13","has_results":false,"results_due":false,"sponsor_name":"University of Chicago","sponsor_slug":"university-of-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07582159","publication_url":"https://clinicaltrials.gov/study/NCT07582159","title":"A Phase 2 Study of Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","has_exemption":false,"start_date":"2026-12-19","completion_date":"2029-04-14","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07274527","publication_url":"https://clinicaltrials.gov/study/NCT07274527","title":"The PEARL Trial: A Randomized Trial of Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Thick Meconium Exposure","has_exemption":false,"start_date":"2026-05-15","completion_date":"2029-04-15","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06367361","publication_url":"https://clinicaltrials.gov/study/NCT06367361","title":"A Non-Inferiority, Randomized, Blind Laboratory Analysis, Controlled Trial Comparing One and Two Doses Regimes of Oxfendazole Versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis","has_exemption":false,"start_date":"2026-08-15","completion_date":"2029-04-15","has_results":false,"results_due":false,"sponsor_name":"Universidad Peruana Cayetano Heredia","sponsor_slug":"universidad-peruana-cayetano-heredia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05739383","publication_url":"https://clinicaltrials.gov/study/NCT05739383","title":"A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)","has_exemption":false,"start_date":"2023-03-09","completion_date":"2029-04-16","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07548164","publication_url":"https://clinicaltrials.gov/study/NCT07548164","title":"Alternative Boost Approaches in Radiation Therapy IRreversible Electroporation Versus RADIAtioN BoosT for Intermediate Risk Prostate Cancer (IRRADIANT)","has_exemption":false,"start_date":"2026-04-16","completion_date":"2029-04-16","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06740526","publication_url":"https://clinicaltrials.gov/study/NCT06740526","title":"A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy","has_exemption":false,"start_date":"2024-11-19","completion_date":"2029-04-17","has_results":false,"results_due":false,"sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","sponsor_slug":"otsuka-pharmaceutical-development-commercialization-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07092514","publication_url":"https://clinicaltrials.gov/study/NCT07092514","title":"Randomized Phase II Trial of Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)","has_exemption":false,"start_date":"2025-10-14","completion_date":"2029-04-17","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07058012","publication_url":"https://clinicaltrials.gov/study/NCT07058012","title":"A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy","has_exemption":false,"start_date":"2026-04-17","completion_date":"2029-04-17","has_results":false,"results_due":false,"sponsor_name":"NSABP Foundation Inc","sponsor_slug":"nsabp-foundation-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05952024","publication_url":"https://clinicaltrials.gov/study/NCT05952024","title":"A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)","has_exemption":false,"start_date":"2024-07-16","completion_date":"2029-04-22","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07325136","publication_url":"https://clinicaltrials.gov/study/NCT07325136","title":"A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer","has_exemption":false,"start_date":"2026-02-03","completion_date":"2029-04-23","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04822181","publication_url":"https://clinicaltrials.gov/study/NCT04822181","title":"The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis","has_exemption":false,"start_date":"2021-04-01","completion_date":"2029-04-25","has_results":false,"results_due":false,"sponsor_name":"Novo Nordisk A/S","sponsor_slug":"novo-nordisk-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05406401","publication_url":"https://clinicaltrials.gov/study/NCT05406401","title":"A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)","has_exemption":false,"start_date":"2022-07-14","completion_date":"2029-04-26","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06780137","publication_url":"https://clinicaltrials.gov/study/NCT06780137","title":"A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer","has_exemption":false,"start_date":"2025-02-27","completion_date":"2029-04-27","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06764875","publication_url":"https://clinicaltrials.gov/study/NCT06764875","title":"A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)","has_exemption":false,"start_date":"2025-03-01","completion_date":"2029-04-27","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06824467","publication_url":"https://clinicaltrials.gov/study/NCT06824467","title":"A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)","has_exemption":false,"start_date":"2025-04-09","completion_date":"2029-04-27","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284433","publication_url":"https://clinicaltrials.gov/study/NCT07284433","title":"A Single-arm, Multicenter, Open-label, Phase I/II Trial of Allo-QuadCAR01-T, an Allogeneic CAR-T-cell Therapy Targeting CD19 and CD20, for the Treatment of Relapsed or Refractory B-cell Malignancies","has_exemption":false,"start_date":"2026-01-06","completion_date":"2029-04-27","has_results":false,"results_due":false,"sponsor_name":"AvenCell Therapeutics, Inc.","sponsor_slug":"avencell-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07366034","publication_url":"https://clinicaltrials.gov/study/NCT07366034","title":"A Study to Evaluate the Dose-exposure, Safety, and Exploratory Efficacy of Nerandomilast in Children and Adolescents From 2 Years to Less Than 18 Years of Age With Fibrosing Interstitial Lung Disease (Part A: Double-blind, Placebo-controlled in Children From 6 to Less Than 18 Years of Age and Open-label Active Treatment in Children From 2 to Less Than 6 Years of Age), Followed by an Open-label Phase With Active Treatment (Part B)","has_exemption":false,"start_date":"2026-07-21","completion_date":"2029-04-27","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07485322","publication_url":"https://clinicaltrials.gov/study/NCT07485322","title":"Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center","has_exemption":false,"start_date":"2026-06-17","completion_date":"2029-04-28","has_results":false,"results_due":false,"sponsor_name":"Inova Health Care Services","sponsor_slug":"inova-health-care-services","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07518186","publication_url":"https://clinicaltrials.gov/study/NCT07518186","title":"A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide","has_exemption":false,"start_date":"2026-05-31","completion_date":"2029-04-29","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04156893","publication_url":"https://clinicaltrials.gov/study/NCT04156893","title":"RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell Disease","has_exemption":false,"start_date":"2020-01-30","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital of Philadelphia","sponsor_slug":"childrens-hospital-of-philadelphia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04499248","publication_url":"https://clinicaltrials.gov/study/NCT04499248","title":"A Phase 1/2 Study to Evaluate the Safety and Efficacy of AGN-193408 SR in Participants With Open-Angle Glaucoma or Ocular Hypertension","has_exemption":false,"start_date":"2020-11-16","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04534205","publication_url":"https://clinicaltrials.gov/study/NCT04534205","title":"An Open-label Phase II/III Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1","has_exemption":false,"start_date":"2021-01-07","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Biontech SE","sponsor_slug":"biontech-se","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04822337","publication_url":"https://clinicaltrials.gov/study/NCT04822337","title":"A Phase I/II Study of Carfilzomib, Lenalidomide, Dexamethasone and the Anti-B-Cell Maturation Antigen (BCMA) Antibody Drug Conjugate Belantamab Mafodotin in Multiple Myeloma","has_exemption":false,"start_date":"2021-05-19","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05362760","publication_url":"https://clinicaltrials.gov/study/NCT05362760","title":"Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management. The MINERVA Trial - A Phase IV Trial","has_exemption":false,"start_date":"2022-04-27","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Prof. Wolfgang Janni","sponsor_slug":"prof-wolfgang-janni","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05462106","publication_url":"https://clinicaltrials.gov/study/NCT05462106","title":"A Phase 1b/2, Multicenter, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-24.060 in Subjects With Prodromal Alzheimer's Disease and in Adults With Down Syndrome (ABATE)","has_exemption":false,"start_date":"2022-06-21","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"AC Immune SA","sponsor_slug":"ac-immune-sa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05484115","publication_url":"https://clinicaltrials.gov/study/NCT05484115","title":"Randomized Controlled Clinical Trial on the Application of Heli-FX EndoAnchors in Conjunction With the Endurant II/IIs Endograft in Infrarenal Aortic Aneurysms With a Wide Infrarenal Neck (HERCULES Trial)","has_exemption":false,"start_date":"2023-05-26","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Rijnstate Hospital","sponsor_slug":"rijnstate-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05701241","publication_url":"https://clinicaltrials.gov/study/NCT05701241","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients - The SAUNA Trial","has_exemption":false,"start_date":"2023-06-28","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"University Hospital, Antwerp","sponsor_slug":"university-hospital-antwerp","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05995353","publication_url":"https://clinicaltrials.gov/study/NCT05995353","title":"A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Crohn's Disease","has_exemption":false,"start_date":"2023-12-11","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05773274","publication_url":"https://clinicaltrials.gov/study/NCT05773274","title":"NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus or Sunitinib or Cabozantinib in Metastatic/Unresectable Gastroenteropancreatic Neuroendocrine Tumours","has_exemption":false,"start_date":"2024-01-12","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06372145","publication_url":"https://clinicaltrials.gov/study/NCT06372145","title":"An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis","has_exemption":false,"start_date":"2024-04-16","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Sanofi","sponsor_slug":"sanofi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06194799","publication_url":"https://clinicaltrials.gov/study/NCT06194799","title":"A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis","has_exemption":false,"start_date":"2024-04-23","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"ACADIA Pharmaceuticals Inc.","sponsor_slug":"acadia-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06029270","publication_url":"https://clinicaltrials.gov/study/NCT06029270","title":"A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)","has_exemption":false,"start_date":"2024-07-15","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06512064","publication_url":"https://clinicaltrials.gov/study/NCT06512064","title":"Advancing Telemedicine in Pulmonology: Acoustic-waveform Respiratory Evaluation (AWARE) Via Sensing and Machine Learning on Smartphones","has_exemption":false,"start_date":"2024-07-23","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Indiana University","sponsor_slug":"indiana-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05563766","publication_url":"https://clinicaltrials.gov/study/NCT05563766","title":"A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer","has_exemption":false,"start_date":"2024-10-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06653153","publication_url":"https://clinicaltrials.gov/study/NCT06653153","title":"A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline","has_exemption":false,"start_date":"2024-10-24","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06246799","publication_url":"https://clinicaltrials.gov/study/NCT06246799","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset Diabetes","has_exemption":false,"start_date":"2024-11-07","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center at San Antonio","sponsor_slug":"the-university-of-texas-health-science-center-at-san-antonio","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06556563","publication_url":"https://clinicaltrials.gov/study/NCT06556563","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).","has_exemption":false,"start_date":"2025-02-03","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"NovoCure GmbH","sponsor_slug":"novocure-gmbh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06932289","publication_url":"https://clinicaltrials.gov/study/NCT06932289","title":"Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions","has_exemption":false,"start_date":"2025-05-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"VA Greater Los Angeles Healthcare System","sponsor_slug":"va-greater-los-angeles-healthcare-system","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06754046","publication_url":"https://clinicaltrials.gov/study/NCT06754046","title":"BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair","has_exemption":false,"start_date":"2025-05-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"University Hospitals Cleveland Medical Center","sponsor_slug":"university-hospitals-cleveland-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06947083","publication_url":"https://clinicaltrials.gov/study/NCT06947083","title":"Phase II Study of Elranatamab as Maintenance Therapy Post Ciltacabtagene-autoleucel(Cilta-cel) in Patients With Clinical High Risk Relapsed Myeloma","has_exemption":false,"start_date":"2025-05-27","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","sponsor_slug":"h-lee-moffitt-cancer-center-and-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07033494","publication_url":"https://clinicaltrials.gov/study/NCT07033494","title":"A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of MK-2214 in Participants With Early Alzheimer's Disease","has_exemption":false,"start_date":"2025-07-16","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06825390","publication_url":"https://clinicaltrials.gov/study/NCT06825390","title":"Mechanistic Clinical Trial of Auricular Stimulation and Cryogenic Auriculotherapy in Patients With Chronic Low-back Pain, Using Functional Near-infrared Spectroscopy and Magnetic Resonance Imaging","has_exemption":false,"start_date":"2025-07-30","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Keith M Vogt","sponsor_slug":"keith-m-vogt","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07131475","publication_url":"https://clinicaltrials.gov/study/NCT07131475","title":"ReBlast Precision (Precision Biomarkers to Detect Brain Injury in Active-Duty United States Special Operations Forces With Repeated Blast Exposure)","has_exemption":false,"start_date":"2025-10-14","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07177339","publication_url":"https://clinicaltrials.gov/study/NCT07177339","title":"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation","has_exemption":false,"start_date":"2025-10-20","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07210255","publication_url":"https://clinicaltrials.gov/study/NCT07210255","title":"A Randomized Controlled Multi-site Trial Evaluating SAINT for Postpartum Depression","has_exemption":false,"start_date":"2025-11-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Magnus Medical","sponsor_slug":"magnus-medical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07155174","publication_url":"https://clinicaltrials.gov/study/NCT07155174","title":"A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)","has_exemption":false,"start_date":"2025-11-25","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07298993","publication_url":"https://clinicaltrials.gov/study/NCT07298993","title":"Determining Evidence in a Placebo-Controlled, Randomized Experiment Studying Continuation vs. Removal of Inessential Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)","has_exemption":false,"start_date":"2026-02-02","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Weill Medical College of Cornell University","sponsor_slug":"weill-medical-college-of-cornell-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03176186","publication_url":"https://clinicaltrials.gov/study/NCT03176186","title":"XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome","has_exemption":false,"start_date":"2026-03-31","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Invero Pharma, Inc.","sponsor_slug":"invero-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07301268","publication_url":"https://clinicaltrials.gov/study/NCT07301268","title":"MC230719 Window Of Opportunity Study Of GI-102 In Patients With Recurrent High-Grade Glioblastoma","has_exemption":false,"start_date":"2026-04-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07516925","publication_url":"https://clinicaltrials.gov/study/NCT07516925","title":"Vonescimab for the Treatment of Previously Treated Advanced or Unresectable Leiomyosarcoma - a Phase II Trial","has_exemption":false,"start_date":"2026-04-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07582523","publication_url":"https://clinicaltrials.gov/study/NCT07582523","title":"Out-of-office Monitoring for Rhythms Of Normal Versus Atrial Fibrillation","has_exemption":false,"start_date":"2026-04-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07423078","publication_url":"https://clinicaltrials.gov/study/NCT07423078","title":"A Phase II Window of Opportunity in Preserving Laryngeal Function (WOLF) Trial","has_exemption":false,"start_date":"2026-04-06","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Matthew Spector","sponsor_slug":"matthew-spector","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07344168","publication_url":"https://clinicaltrials.gov/study/NCT07344168","title":"A Prospective, Open-label, Single Arm Study to Evaluate the Safety and Effectiveness of the EndoArt® in Subjects With Chronic Corneal Edema in Whom Multiple Prior Keratoplasty (EK/PK) Have Failed, and Who Are Not Reasonable Candidates for Any Form of Corneal Transplant, Including Penetrating Keratoplasty","has_exemption":false,"start_date":"2026-05-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Eye-yon Medical","sponsor_slug":"eye-yon-medical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07512284","publication_url":"https://clinicaltrials.gov/study/NCT07512284","title":"Mindfulness Engaged Neurostimulation for Depression","has_exemption":false,"start_date":"2026-05-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"University of California, San Diego","sponsor_slug":"university-of-california-san-diego","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07422480","publication_url":"https://clinicaltrials.gov/study/NCT07422480","title":"A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions","has_exemption":false,"start_date":"2026-05-21","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07492641","publication_url":"https://clinicaltrials.gov/study/NCT07492641","title":"An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease","has_exemption":false,"start_date":"2026-05-22","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"BeOne Medicines","sponsor_slug":"beone-medicines","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07043608","publication_url":"https://clinicaltrials.gov/study/NCT07043608","title":"A Phase II Study of Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases in Patients Previously Treated With Immune Checkpoint Inhibitors","has_exemption":false,"start_date":"2026-06-10","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Kelly Fitzgerald, MD","sponsor_slug":"kelly-fitzgerald-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07554638","publication_url":"https://clinicaltrials.gov/study/NCT07554638","title":"Identifying Therapeutic Mechanisms for Incretin-Based Treatment in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF)","has_exemption":false,"start_date":"2026-06-30","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Columbia University","sponsor_slug":"columbia-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07592858","publication_url":"https://clinicaltrials.gov/study/NCT07592858","title":"Use of Bile Acid Binding Resins to Decrease Systemic Per- and Polyfluoroalkyl Substance (PFAS) Levels and Improve Serum Lipid Profiles in Veterans: PFAS Reduction in Veterans Via Colesevalem Study (PAVERS) Study","has_exemption":false,"start_date":"2026-07-01","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"University of Rhode Island","sponsor_slug":"university-of-rhode-island","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07153055","publication_url":"https://clinicaltrials.gov/study/NCT07153055","title":"Phase I/II Trial of Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Misty Shields","sponsor_slug":"misty-shields","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07712562","publication_url":"https://clinicaltrials.gov/study/NCT07712562","title":"A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Dibotatug in Adults With Bone Marrow Failure Syndromes","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Dren Bio","sponsor_slug":"dren-bio","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07686081","publication_url":"https://clinicaltrials.gov/study/NCT07686081","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ponesimod in Patients With Moderately to Severely Active Ulcerative Colitis","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Vanda Pharmaceuticals","sponsor_slug":"vanda-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07756736","publication_url":"https://clinicaltrials.gov/study/NCT07756736","title":"Psilocybin Recovery Intervention for Stopping Methamphetamine Use","has_exemption":false,"start_date":"2026-11-30","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Nicky Mehtani, MD, MPH","sponsor_slug":"nicky-mehtani-md-mph","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07743489","publication_url":"https://clinicaltrials.gov/study/NCT07743489","title":"Light for Ulcer Management by Infection Elimination and Resistance Enhancement (LUMIERE)","has_exemption":false,"start_date":"2027-01-31","completion_date":"2029-04-30","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05556902","publication_url":"https://clinicaltrials.gov/study/NCT05556902","title":"Therapeutic Mechanisms of Epidural Spinal Cord Stimulation","has_exemption":false,"start_date":"2022-08-02","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06345963","publication_url":"https://clinicaltrials.gov/study/NCT06345963","title":"Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)","has_exemption":false,"start_date":"2024-05-21","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center, Houston","sponsor_slug":"the-university-of-texas-health-science-center-houston","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06327100","publication_url":"https://clinicaltrials.gov/study/NCT06327100","title":"Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","has_exemption":false,"start_date":"2024-08-01","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06494111","publication_url":"https://clinicaltrials.gov/study/NCT06494111","title":"Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)","has_exemption":false,"start_date":"2025-02-13","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06897930","publication_url":"https://clinicaltrials.gov/study/NCT06897930","title":"A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE)","has_exemption":false,"start_date":"2025-04-21","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06909110","publication_url":"https://clinicaltrials.gov/study/NCT06909110","title":"Viral Specific T-Lymphocytes by Cytokine Capture System (CCS) to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus After Hematopoietic Cell Transplantation or Solid Organ Transplantation and in Patients With Compromised Immunity","has_exemption":false,"start_date":"2025-04-30","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"Jessie L. Alexander","sponsor_slug":"jessie-l-alexander","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06261840","publication_url":"https://clinicaltrials.gov/study/NCT06261840","title":"Refining Treatment Options for Trichomonas Vaginalis Infection in Women and Men: A Comparative Analysis of Oral Multi-Dose Metronidazole and Single-Dose Secnidazole","has_exemption":false,"start_date":"2025-05-06","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"Tulane University","sponsor_slug":"tulane-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06961916","publication_url":"https://clinicaltrials.gov/study/NCT06961916","title":"Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 2)","has_exemption":false,"start_date":"2025-06-03","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center, Houston","sponsor_slug":"the-university-of-texas-health-science-center-houston","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06999577","publication_url":"https://clinicaltrials.gov/study/NCT06999577","title":"The MVP Trial: A Randomized Controlled Trial of Mechanism Guided vs PPI Strategy for Laryngopharyngeal Reflux","has_exemption":false,"start_date":"2025-06-04","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"University of California, San Diego","sponsor_slug":"university-of-california-san-diego","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06501820","publication_url":"https://clinicaltrials.gov/study/NCT06501820","title":"Neural Control of Gait & Navigation in ADRD, Aim 3 Clinical Trial","has_exemption":false,"start_date":"2025-11-13","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"University of Florida","sponsor_slug":"university-of-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05950659","publication_url":"https://clinicaltrials.gov/study/NCT05950659","title":"Prevention of Foot Ulcer Recurrence in Individuals Who Are at High-risk for Diabetic Foot Complications Using the Orpyx Sensory Insole System: a Multisite, Randomized, Controlled Trial","has_exemption":false,"start_date":"2026-04-22","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07530796","publication_url":"https://clinicaltrials.gov/study/NCT07530796","title":"An Open-Label, Single Center, Phase 1/2 Study to Evaluate the Safety and Efficacy of DANAGALEX (scAAV9/AGA) in Participants With Aspartylglucosaminuria (AGU)","has_exemption":false,"start_date":"2026-05-01","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"Rare Trait Hope","sponsor_slug":"rare-trait-hope","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07553975","publication_url":"https://clinicaltrials.gov/study/NCT07553975","title":"Randomized Study Evaluating Cost of Arthrex Nano Arthroscopy Products in Arthroscopic Knee ACL Surgery Versus Conventional Arthroscopy","has_exemption":false,"start_date":"2026-05-01","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"University of Colorado, Denver","sponsor_slug":"university-of-colorado-denver","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07413939","publication_url":"https://clinicaltrials.gov/study/NCT07413939","title":"A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases","has_exemption":false,"start_date":"2026-05-21","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07024706","publication_url":"https://clinicaltrials.gov/study/NCT07024706","title":"The MAVRiC Study: A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab","has_exemption":false,"start_date":"2026-06-04","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07772349","publication_url":"https://clinicaltrials.gov/study/NCT07772349","title":"Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3)","has_exemption":false,"start_date":"2026-10-01","completion_date":"2029-05-01","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center, Houston","sponsor_slug":"the-university-of-texas-health-science-center-houston","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06137144","publication_url":"https://clinicaltrials.gov/study/NCT06137144","title":"A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies","has_exemption":false,"start_date":"2024-01-23","completion_date":"2029-05-03","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07197866","publication_url":"https://clinicaltrials.gov/study/NCT07197866","title":"An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy","has_exemption":false,"start_date":"2025-09-30","completion_date":"2029-05-03","has_results":false,"results_due":false,"sponsor_name":"Teva Branded Pharmaceutical Products R&D LLC","sponsor_slug":"teva-branded-pharmaceutical-products-rd-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07076121","publication_url":"https://clinicaltrials.gov/study/NCT07076121","title":"A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion","has_exemption":false,"start_date":"2025-10-23","completion_date":"2029-05-03","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07712380","publication_url":"https://clinicaltrials.gov/study/NCT07712380","title":"A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Above Who Are at Risk for Cardiovascular Events","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-05-04","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06976476","publication_url":"https://clinicaltrials.gov/study/NCT06976476","title":"Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)","has_exemption":false,"start_date":"2025-05-08","completion_date":"2029-05-08","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06630416","publication_url":"https://clinicaltrials.gov/study/NCT06630416","title":"A Phase II Trial to Evaluate Pemetrexed Response in Relation to Tumor Alterations of Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma and Other Solid Tumors","has_exemption":false,"start_date":"2024-11-27","completion_date":"2029-05-10","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06745323","publication_url":"https://clinicaltrials.gov/study/NCT06745323","title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)","has_exemption":false,"start_date":"2025-02-26","completion_date":"2029-05-10","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07252232","publication_url":"https://clinicaltrials.gov/study/NCT07252232","title":"RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","has_exemption":false,"start_date":"2025-12-15","completion_date":"2029-05-10","has_results":false,"results_due":false,"sponsor_name":"Revolution Medicines, Inc.","sponsor_slug":"revolution-medicines-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05555732","publication_url":"https://clinicaltrials.gov/study/NCT05555732","title":"A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)","has_exemption":false,"start_date":"2023-01-11","completion_date":"2029-05-11","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07184931","publication_url":"https://clinicaltrials.gov/study/NCT07184931","title":"A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Induction Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease","has_exemption":false,"start_date":"2025-10-01","completion_date":"2029-05-14","has_results":false,"results_due":false,"sponsor_name":"Sanofi","sponsor_slug":"sanofi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07201922","publication_url":"https://clinicaltrials.gov/study/NCT07201922","title":"A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)","has_exemption":false,"start_date":"2026-02-10","completion_date":"2029-05-14","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05564390","publication_url":"https://clinicaltrials.gov/study/NCT05564390","title":"Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials","has_exemption":false,"start_date":"2024-06-18","completion_date":"2029-05-15","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06317649","publication_url":"https://clinicaltrials.gov/study/NCT06317649","title":"A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy","has_exemption":false,"start_date":"2024-09-27","completion_date":"2029-05-15","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05458297","publication_url":"https://clinicaltrials.gov/study/NCT05458297","title":"A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)","has_exemption":false,"start_date":"2022-07-21","completion_date":"2029-05-17","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05878717","publication_url":"https://clinicaltrials.gov/study/NCT05878717","title":"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)","has_exemption":false,"start_date":"2023-09-13","completion_date":"2029-05-17","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03591510","publication_url":"https://clinicaltrials.gov/study/NCT03591510","title":"A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML","has_exemption":false,"start_date":"2019-03-13","completion_date":"2029-05-18","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06662448","publication_url":"https://clinicaltrials.gov/study/NCT06662448","title":"An Open-Label Study to Evaluate the Efficacy and Feasibility of Home-Based Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies","has_exemption":false,"start_date":"2024-11-18","completion_date":"2029-05-18","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07675499","publication_url":"https://clinicaltrials.gov/study/NCT07675499","title":"Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes","has_exemption":false,"start_date":"2026-08-03","completion_date":"2029-05-18","has_results":false,"results_due":false,"sponsor_name":"Rutgers, The State University of New Jersey","sponsor_slug":"rutgers-the-state-university-of-new-jersey","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05826990","publication_url":"https://clinicaltrials.gov/study/NCT05826990","title":"Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI","has_exemption":false,"start_date":"2023-09-11","completion_date":"2029-05-21","has_results":false,"results_due":false,"sponsor_name":"Orchid Pharma Europe GmbH","sponsor_slug":"orchid-pharma-europe-gmbh","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06430788","publication_url":"https://clinicaltrials.gov/study/NCT06430788","title":"Phase 2a/2b Study Emapalumab: A Window of Opportunity in Pediatric Aplastic Anemia","has_exemption":false,"start_date":"2024-05-21","completion_date":"2029-05-21","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07006506","publication_url":"https://clinicaltrials.gov/study/NCT07006506","title":"Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation","has_exemption":false,"start_date":"2025-05-21","completion_date":"2029-05-21","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07222761","publication_url":"https://clinicaltrials.gov/study/NCT07222761","title":"An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma","has_exemption":false,"start_date":"2026-01-02","completion_date":"2029-05-21","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05485961","publication_url":"https://clinicaltrials.gov/study/NCT05485961","title":"A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis","has_exemption":false,"start_date":"2022-10-21","completion_date":"2029-05-22","has_results":false,"results_due":false,"sponsor_name":"CSL Behring","sponsor_slug":"csl-behring","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06667076","publication_url":"https://clinicaltrials.gov/study/NCT06667076","title":"A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2024-12-16","completion_date":"2029-05-23","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07525375","publication_url":"https://clinicaltrials.gov/study/NCT07525375","title":"A Phase II, Randomized, Double-blind, 3-Period Cross-over, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium (GP) Versus Placebo in Participants of 4 to Less Than 12 Years of Age With Asthma Receiving Background Budesonide and Formoterol Fumarate (BFF)","has_exemption":false,"start_date":"2026-04-14","completion_date":"2029-05-23","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07332481","publication_url":"https://clinicaltrials.gov/study/NCT07332481","title":"A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-1)","has_exemption":false,"start_date":"2026-03-10","completion_date":"2029-05-24","has_results":false,"results_due":false,"sponsor_name":"EMD Serono Research & Development Institute, Inc.","sponsor_slug":"emd-serono-research-development-institute-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03965234","publication_url":"https://clinicaltrials.gov/study/NCT03965234","title":"Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases","has_exemption":false,"start_date":"2020-07-16","completion_date":"2029-05-25","has_results":false,"results_due":false,"sponsor_name":"Roswell Park Cancer Institute","sponsor_slug":"roswell-park-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05285826","publication_url":"https://clinicaltrials.gov/study/NCT05285826","title":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy, Immunogenicity, and Safety of V503, a 9-Valent Human Papillomavirus (HPV) Vaccine, in Chinese Males 20 to 45 Years of Age","has_exemption":false,"start_date":"2022-02-18","completion_date":"2029-05-25","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07355218","publication_url":"https://clinicaltrials.gov/study/NCT07355218","title":"A Phase 3, Randomized, Double-Blind,Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants With Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care (ELOWEN-2)","has_exemption":false,"start_date":"2026-04-01","completion_date":"2029-05-25","has_results":false,"results_due":false,"sponsor_name":"EMD Serono Research & Development Institute, Inc.","sponsor_slug":"emd-serono-research-development-institute-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07631000","publication_url":"https://clinicaltrials.gov/study/NCT07631000","title":"A Phase 2, Single-arm Study of Cadonilimab and FLOT Chemotherapy in Patients With Locally Advanced, Resectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","has_exemption":false,"start_date":"2026-05-27","completion_date":"2029-05-27","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07287982","publication_url":"https://clinicaltrials.gov/study/NCT07287982","title":"A Phase 2 Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy","has_exemption":false,"start_date":"2025-12-19","completion_date":"2029-05-28","has_results":false,"results_due":false,"sponsor_name":"argenx","sponsor_slug":"argenx","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04776252","publication_url":"https://clinicaltrials.gov/study/NCT04776252","title":"A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study","has_exemption":false,"start_date":"2021-09-15","completion_date":"2029-05-29","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04802759","publication_url":"https://clinicaltrials.gov/study/NCT04802759","title":"A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)","has_exemption":false,"start_date":"2021-06-22","completion_date":"2029-05-30","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04669171","publication_url":"https://clinicaltrials.gov/study/NCT04669171","title":"A Global Multicenter Phase 1/2 Trial of EO2463, a Novel Microbial-Derived Peptide Therapeutic Vaccine, as Monotherapy, and in Combination With Lenalidomide and Rituximab, for Treatment of Patients With Indolent Non-Hodgkin's Lymphoma","has_exemption":false,"start_date":"2021-07-05","completion_date":"2029-05-30","has_results":false,"results_due":false,"sponsor_name":"Enterome","sponsor_slug":"enterome","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06599099","publication_url":"https://clinicaltrials.gov/study/NCT06599099","title":"Building Mood State Classifiers to Inform Deep Brain Stimulation of Treatment-Resistant Bipolar Depression","has_exemption":false,"start_date":"2025-01-01","completion_date":"2029-05-30","has_results":false,"results_due":false,"sponsor_name":"Wayne Goodman MD","sponsor_slug":"wayne-goodman-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06654882","publication_url":"https://clinicaltrials.gov/study/NCT06654882","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","has_exemption":false,"start_date":"2026-01-09","completion_date":"2029-05-30","has_results":false,"results_due":false,"sponsor_name":"Duke University","sponsor_slug":"duke-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07592611","publication_url":"https://clinicaltrials.gov/study/NCT07592611","title":"Deep Brain Stimulation in Treatment Resistant Schizophrenia","has_exemption":false,"start_date":"2026-09-01","completion_date":"2029-05-30","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03121001","publication_url":"https://clinicaltrials.gov/study/NCT03121001","title":"A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease","has_exemption":false,"start_date":"2017-03-20","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Illinois at Chicago","sponsor_slug":"university-of-illinois-at-chicago","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03705585","publication_url":"https://clinicaltrials.gov/study/NCT03705585","title":"CVD 38000: Immunity, Microbiome, Epigenetics, and a Systems Biology Approach to the Study of Responses to Vaccination With Typhoid and/or Cholera","has_exemption":false,"start_date":"2018-11-05","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Maryland, Baltimore","sponsor_slug":"university-of-maryland-baltimore","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04339764","publication_url":"https://clinicaltrials.gov/study/NCT04339764","title":"A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration","has_exemption":false,"start_date":"2020-09-23","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"National Eye Institute (NEI)","sponsor_slug":"national-eye-institute-nei","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04692493","publication_url":"https://clinicaltrials.gov/study/NCT04692493","title":"A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)","has_exemption":false,"start_date":"2021-09-22","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Alabama at Birmingham","sponsor_slug":"university-of-alabama-at-birmingham","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05318573","publication_url":"https://clinicaltrials.gov/study/NCT05318573","title":"A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors","has_exemption":false,"start_date":"2022-06-01","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Fujifilm Pharmaceuticals U.S.A., Inc.","sponsor_slug":"fujifilm-pharmaceuticals-usa-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06016842","publication_url":"https://clinicaltrials.gov/study/NCT06016842","title":"A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)","has_exemption":false,"start_date":"2023-08-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05537220","publication_url":"https://clinicaltrials.gov/study/NCT05537220","title":"NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa","has_exemption":false,"start_date":"2023-10-11","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05890729","publication_url":"https://clinicaltrials.gov/study/NCT05890729","title":"A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations","has_exemption":false,"start_date":"2023-11-10","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Xentria, Inc.","sponsor_slug":"xentria-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05940207","publication_url":"https://clinicaltrials.gov/study/NCT05940207","title":"Safety Testing of Hydrogen Peroxide-Generating e-Bandage on Normal Human Skin","has_exemption":false,"start_date":"2024-03-27","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06545136","publication_url":"https://clinicaltrials.gov/study/NCT06545136","title":"A Multicenter, Long-term, Follow-up Study to Investigate the Safety and Durability of Response Following Dosing of an Adeno-associated Viral Vector (FLT201) in Subjects With Gaucher Disease (GALILEO-2)","has_exemption":false,"start_date":"2024-05-13","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Spur Therapeutics","sponsor_slug":"spur-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06295731","publication_url":"https://clinicaltrials.gov/study/NCT06295731","title":"A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)","has_exemption":false,"start_date":"2024-05-14","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Inhibrx Biosciences, Inc","sponsor_slug":"inhibrx-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06374875","publication_url":"https://clinicaltrials.gov/study/NCT06374875","title":"A Prospective Multicenter International Randomized Controlled Trial Comparing Surgical and Medical Therapies in the Treatment of Advanced Metabolic Dysfunction Associated Steatohepatitis","has_exemption":false,"start_date":"2024-07-11","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"The Cleveland Clinic","sponsor_slug":"the-cleveland-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06485206","publication_url":"https://clinicaltrials.gov/study/NCT06485206","title":"A Clinical Investigation Evaluating Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.","has_exemption":false,"start_date":"2024-09-01","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Highridge Medical","sponsor_slug":"highridge-medical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06789848","publication_url":"https://clinicaltrials.gov/study/NCT06789848","title":"Phase II Basket Trial of Ligufalimab (AK117) and Cadonilimab (AK104) in Advanced Hepatobiliary Cancers","has_exemption":false,"start_date":"2025-02-18","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Texas Southwestern Medical Center","sponsor_slug":"university-of-texas-southwestern-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06682442","publication_url":"https://clinicaltrials.gov/study/NCT06682442","title":"Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma","has_exemption":false,"start_date":"2025-03-18","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06604520","publication_url":"https://clinicaltrials.gov/study/NCT06604520","title":"Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia","has_exemption":false,"start_date":"2025-03-20","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06907290","publication_url":"https://clinicaltrials.gov/study/NCT06907290","title":"A Global, Randomized, Open-label, Multicenter, Phase 2b/3 Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-1)","has_exemption":false,"start_date":"2025-03-25","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Mirum Pharmaceuticals, Inc.","sponsor_slug":"mirum-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06890598","publication_url":"https://clinicaltrials.gov/study/NCT06890598","title":"A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02","has_exemption":false,"start_date":"2025-03-27","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06966401","publication_url":"https://clinicaltrials.gov/study/NCT06966401","title":"A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)","has_exemption":false,"start_date":"2025-04-16","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Neurocrine Biosciences","sponsor_slug":"neurocrine-biosciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06768905","publication_url":"https://clinicaltrials.gov/study/NCT06768905","title":"IOMAB-ACT: A Phase Ib/II Multi-institutional Study of 131 I-Apamistamab Followed by CD19-Targeted CAR-T Cell Therapy for Patients With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","has_exemption":false,"start_date":"2025-04-25","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Texas Southwestern Medical Center","sponsor_slug":"university-of-texas-southwestern-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06812715","publication_url":"https://clinicaltrials.gov/study/NCT06812715","title":"Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib","has_exemption":false,"start_date":"2025-05-05","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Peter MacCallum Cancer Centre, Australia","sponsor_slug":"peter-maccallum-cancer-centre-australia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06512194","publication_url":"https://clinicaltrials.gov/study/NCT06512194","title":"An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)","has_exemption":false,"start_date":"2025-05-13","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Charles Raison","sponsor_slug":"charles-raison","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07059065","publication_url":"https://clinicaltrials.gov/study/NCT07059065","title":"A Post-market, Prospective, Controlled, Multicenter Clinical Study to Evaluate Radiographic Fusion of FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute in Subjects Who Undergo a Lumbar Posterolateral Fusion Surgery","has_exemption":false,"start_date":"2025-08-15","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"DePuy Synthes Products, Inc.","sponsor_slug":"depuy-synthes-products-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218796","publication_url":"https://clinicaltrials.gov/study/NCT07218796","title":"A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy of the Bimatoprost Implant System (78 mcg) Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%,","has_exemption":false,"start_date":"2025-10-28","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"SpyGlass Pharma, Inc.","sponsor_slug":"spyglass-pharma-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06961357","publication_url":"https://clinicaltrials.gov/study/NCT06961357","title":"Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Melanoma","has_exemption":false,"start_date":"2025-12-03","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","sponsor_slug":"h-lee-moffitt-cancer-center-and-research-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07174336","publication_url":"https://clinicaltrials.gov/study/NCT07174336","title":"A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)","has_exemption":false,"start_date":"2025-12-22","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07285694","publication_url":"https://clinicaltrials.gov/study/NCT07285694","title":"An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)","has_exemption":false,"start_date":"2026-01-09","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Arsenal Biosciences, Inc.","sponsor_slug":"arsenal-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06954129","publication_url":"https://clinicaltrials.gov/study/NCT06954129","title":"Markers of Nephrotoxicity During Treatment With Antibiotic Combinations: A Pragmatic Clinical Trial","has_exemption":false,"start_date":"2026-01-28","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06875128","publication_url":"https://clinicaltrials.gov/study/NCT06875128","title":"An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients With Metastatic Breast Cancer With Liver Dominant Disease","has_exemption":false,"start_date":"2026-01-29","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Delcath Systems Inc.","sponsor_slug":"delcath-systems-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07397338","publication_url":"https://clinicaltrials.gov/study/NCT07397338","title":"A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors","has_exemption":false,"start_date":"2026-01-30","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Revolution Medicines, Inc.","sponsor_slug":"revolution-medicines-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07436156","publication_url":"https://clinicaltrials.gov/study/NCT07436156","title":"SUMMIT RISE Study of Acute Ischemic Stroke Patients Evaluating the Route 92 Medical Reperfusion Systems.","has_exemption":false,"start_date":"2026-02-12","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Route 92 Medical, Inc.","sponsor_slug":"route-92-medical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07491497","publication_url":"https://clinicaltrials.gov/study/NCT07491497","title":"A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC","has_exemption":false,"start_date":"2026-03-11","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"TRIANA Biomedicines, Inc.","sponsor_slug":"triana-biomedicines-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06773936","publication_url":"https://clinicaltrials.gov/study/NCT06773936","title":"A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","has_exemption":false,"start_date":"2026-04-13","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"SWOG Cancer Research Network","sponsor_slug":"swog-cancer-research-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07504796","publication_url":"https://clinicaltrials.gov/study/NCT07504796","title":"A Multi-center Trial Evaluating the ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab for Advanced Melanoma","has_exemption":false,"start_date":"2026-04-13","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07558733","publication_url":"https://clinicaltrials.gov/study/NCT07558733","title":"Open-Label Umbrella Study to Evaluate Safety and Efficacy of Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer","has_exemption":false,"start_date":"2026-04-22","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Faeth Therapeutics","sponsor_slug":"faeth-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07424092","publication_url":"https://clinicaltrials.gov/study/NCT07424092","title":"Intratumoral DNX-2401 Administration for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients","has_exemption":false,"start_date":"2026-05-12","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","sponsor_slug":"clinica-universidad-de-navarra-universidad-de-navarra","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07612215","publication_url":"https://clinicaltrials.gov/study/NCT07612215","title":"Elacestrant in Advanced Triple Positive Breast Cancer, a Phase II Evaluation (ELATE)","has_exemption":false,"start_date":"2026-05-13","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07525206","publication_url":"https://clinicaltrials.gov/study/NCT07525206","title":"An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer","has_exemption":false,"start_date":"2026-05-22","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07574632","publication_url":"https://clinicaltrials.gov/study/NCT07574632","title":"The RESILIENT Scoliosis Brace System Clinical Trial (RESILIENT)","has_exemption":false,"start_date":"2026-05-28","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Thinks Works, PBC","sponsor_slug":"thinks-works-pbc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07472439","publication_url":"https://clinicaltrials.gov/study/NCT07472439","title":"Randomized Controlled Trial of the Auryon Atherectomy System Used in Combination With Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects With Critical Limb Ischemia","has_exemption":false,"start_date":"2026-05-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Angiodynamics, Inc.","sponsor_slug":"angiodynamics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07566234","publication_url":"https://clinicaltrials.gov/study/NCT07566234","title":"Myopia Prevention Study in Chinese Population With Dual Focus Myopia Control Lenses.","has_exemption":false,"start_date":"2026-06-06","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"CooperVision International Limited (CVIL)","sponsor_slug":"coopervision-international-limited-cvil","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07071935","publication_url":"https://clinicaltrials.gov/study/NCT07071935","title":"A Pilot Randomized Clinical Trial of Early Ventilation in Amyotrophic Lateral Sclerosis (EVENT ALS)","has_exemption":false,"start_date":"2026-06-11","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07501078","publication_url":"https://clinicaltrials.gov/study/NCT07501078","title":"Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation","has_exemption":false,"start_date":"2026-07-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Muhammad N Aslam, MD","sponsor_slug":"muhammad-n-aslam-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07631572","publication_url":"https://clinicaltrials.gov/study/NCT07631572","title":"Phase II Clinical Trial of Cesium-131 Low-dose Rate Interstitial Brachytherapy as an Organ-preserving Irradiation Technique for Recurrent Cervical and Endometrial Cancer","has_exemption":false,"start_date":"2026-07-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Denise Fabian","sponsor_slug":"denise-fabian","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07665684","publication_url":"https://clinicaltrials.gov/study/NCT07665684","title":"Phase Ib/II Study of Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer","has_exemption":false,"start_date":"2026-07-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"University Health Network, Toronto","sponsor_slug":"university-health-network-toronto","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07675811","publication_url":"https://clinicaltrials.gov/study/NCT07675811","title":"A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy","has_exemption":false,"start_date":"2026-07-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06899165","publication_url":"https://clinicaltrials.gov/study/NCT06899165","title":"Processing Intergenerational Trauma With Psilocybin-Assisted Therapy","has_exemption":false,"start_date":"2026-08-28","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Rachel Yehuda","sponsor_slug":"rachel-yehuda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07587242","publication_url":"https://clinicaltrials.gov/study/NCT07587242","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Avidity Biosciences, Inc.","sponsor_slug":"avidity-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07592910","publication_url":"https://clinicaltrials.gov/study/NCT07592910","title":"A Phase 2, Open-label, Single-Arm Study of Mevrometostat Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Following Prior Androgen Receptor Pathway Inhibitor Therapy (MOMENT)","has_exemption":false,"start_date":"2026-08-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Prostate Cancer Clinical Trials Consortium","sponsor_slug":"prostate-cancer-clinical-trials-consortium","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07608718","publication_url":"https://clinicaltrials.gov/study/NCT07608718","title":"A Single Arm Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With Soft Tissue or Visceral Metastases","has_exemption":false,"start_date":"2026-09-30","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Pedro Barata, MD, MSc","sponsor_slug":"pedro-barata-md-msc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07538609","publication_url":"https://clinicaltrials.gov/study/NCT07538609","title":"The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study","has_exemption":false,"start_date":"2026-10-07","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"W.L.Gore & Associates","sponsor_slug":"wlgore-associates","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07720219","publication_url":"https://clinicaltrials.gov/study/NCT07720219","title":"Obstructive Sleep Apnea Severity Reduction by AdIpose CryolysiS","has_exemption":false,"start_date":"2026-10-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Cryosa, Inc.","sponsor_slug":"cryosa-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07639684","publication_url":"https://clinicaltrials.gov/study/NCT07639684","title":"Metabolic Effects of Endoscopic Sleeve Gastroplasty in Obese Adults With Type 2 Diabetes: Evaluation of Glycemic Control, Insulin Use and Obesity Response","has_exemption":false,"start_date":"2027-02-28","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Boston Scientific Corporation","sponsor_slug":"boston-scientific-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07712757","publication_url":"https://clinicaltrials.gov/study/NCT07712757","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Safusidenib in Participants With Grade 2 Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma","has_exemption":false,"start_date":"2027-03-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Nuvation Bio, Inc.","sponsor_slug":"nuvation-bio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06769854","publication_url":"https://clinicaltrials.gov/study/NCT06769854","title":"Defining the Safety and Efficacy of POSterIor Tibial NeRve StimulatiON in Children","has_exemption":false,"start_date":"2027-04-01","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Chi Dang Hornik","sponsor_slug":"chi-dang-hornik","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06816433","publication_url":"https://clinicaltrials.gov/study/NCT06816433","title":"A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members, Veterans, and Non-Veteran Civilians With PTSD","has_exemption":false,"start_date":"2028-05-31","completion_date":"2029-05-31","has_results":false,"results_due":false,"sponsor_name":"Global Coalition for Adaptive Research","sponsor_slug":"global-coalition-for-adaptive-research","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03258567","publication_url":"https://clinicaltrials.gov/study/NCT03258567","title":"Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas","has_exemption":false,"start_date":"2018-04-26","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06978088","publication_url":"https://clinicaltrials.gov/study/NCT06978088","title":"A Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This","has_exemption":false,"start_date":"2025-06-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Zulfa Omer","sponsor_slug":"zulfa-omer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07129993","publication_url":"https://clinicaltrials.gov/study/NCT07129993","title":"A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)","has_exemption":false,"start_date":"2025-09-26","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06816927","publication_url":"https://clinicaltrials.gov/study/NCT06816927","title":"A Multi-Center, Randomized, Phase 2 Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT)","has_exemption":false,"start_date":"2025-11-28","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Duke University","sponsor_slug":"duke-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06944145","publication_url":"https://clinicaltrials.gov/study/NCT06944145","title":"A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Monotherapy (5-alpha Reductase Inhibitor + Placebo) in Adult Patients With Benign Prostatic Hyperplasia (BPH)","has_exemption":false,"start_date":"2025-12-03","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Beth Israel Deaconess Medical Center","sponsor_slug":"beth-israel-deaconess-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05899764","publication_url":"https://clinicaltrials.gov/study/NCT05899764","title":"Epileptic Hippocampus in Alzheimer's Disease","has_exemption":false,"start_date":"2026-01-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"University of California, Los Angeles","sponsor_slug":"university-of-california-los-angeles","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07490600","publication_url":"https://clinicaltrials.gov/study/NCT07490600","title":"Contingency Management Plus Deep Transcranial Magnetic Stimulation for the Treatment","has_exemption":false,"start_date":"2026-04-21","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center, Houston","sponsor_slug":"the-university-of-texas-health-science-center-houston","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07541209","publication_url":"https://clinicaltrials.gov/study/NCT07541209","title":"A Phase 1/2 Open-label First-in-Human Dose-Escalating Safety and Efficacy Study Evaluating Subcutaneous Administration of PTH-IA in Adults and Children With Jansen s Metaphyseal Chondrodysplasia (JMC)","has_exemption":false,"start_date":"2026-05-27","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"National Institute of Dental and Craniofacial Research (NIDCR)","sponsor_slug":"national-institute-of-dental-and-craniofacial-research-nidcr","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07361484","publication_url":"https://clinicaltrials.gov/study/NCT07361484","title":"A Global, Multicenter, Randomized, Double-blinded, Phase 3 Study of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer With EGFR, ALK, ROS, and RET Wild Type After Progressing on Prior Immunotherapy (Anti-PD-1/L1 Antibody) and Platinum-based Chemotherapy (DUBLIN-4)","has_exemption":false,"start_date":"2026-06-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"BeyondSpring Pharmaceuticals Inc.","sponsor_slug":"beyondspring-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07099638","publication_url":"https://clinicaltrials.gov/study/NCT07099638","title":"Randomized Factorial Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation","has_exemption":false,"start_date":"2026-07-21","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"University of Oklahoma","sponsor_slug":"university-of-oklahoma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06863402","publication_url":"https://clinicaltrials.gov/study/NCT06863402","title":"Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study","has_exemption":false,"start_date":"2026-08-15","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Roswell Park Cancer Institute","sponsor_slug":"roswell-park-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07543172","publication_url":"https://clinicaltrials.gov/study/NCT07543172","title":"Phase II Study of CIMAVAX-EGF in Combination With KRAS G12C Inhibitors as Treatment for Advanced Stage KRAS G12C Mutated NSCLC","has_exemption":false,"start_date":"2026-09-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Roswell Park Cancer Institute","sponsor_slug":"roswell-park-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07578649","publication_url":"https://clinicaltrials.gov/study/NCT07578649","title":"AN INTERVENTIONAL PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER","has_exemption":false,"start_date":"2026-10-09","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07466498","publication_url":"https://clinicaltrials.gov/study/NCT07466498","title":"Estrogen for Quality-of-Life and Immune Modulation in Prostate Cancer (EQUIP)","has_exemption":false,"start_date":"2026-11-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"University of Washington","sponsor_slug":"university-of-washington","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07229339","publication_url":"https://clinicaltrials.gov/study/NCT07229339","title":"Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations","has_exemption":false,"start_date":"2027-06-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07430332","publication_url":"https://clinicaltrials.gov/study/NCT07430332","title":"Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function","has_exemption":false,"start_date":"2027-09-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07011758","publication_url":"https://clinicaltrials.gov/study/NCT07011758","title":"Dynamic Treatment Regimes for Personalized Opioid Use Disorder Care","has_exemption":false,"start_date":"2028-07-01","completion_date":"2029-06-01","has_results":false,"results_due":false,"sponsor_name":"Brigham and Women's Hospital","sponsor_slug":"brigham-and-womens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06900595","publication_url":"https://clinicaltrials.gov/study/NCT06900595","title":"A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer","has_exemption":false,"start_date":"2026-02-22","completion_date":"2029-06-02","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07286214","publication_url":"https://clinicaltrials.gov/study/NCT07286214","title":"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Each of Two Dose Levels of Sarilumab in Adults With Early Polymyalgia Rheumatica","has_exemption":false,"start_date":"2026-05-12","completion_date":"2029-06-04","has_results":false,"results_due":false,"sponsor_name":"Sanofi","sponsor_slug":"sanofi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06632457","publication_url":"https://clinicaltrials.gov/study/NCT06632457","title":"A Phase III Double-blind, Randomised, Placebo-controlled Trial to Evaluate Liver-related Clinical Outcomes and Safety of Once Weekly Injected Survodutide in Participants With Compensated Non-alcoholic Steatohepatitis/Metabolic Dysfunction Associated Steatohepatitis (NASH/MASH) Cirrhosis","has_exemption":false,"start_date":"2024-11-07","completion_date":"2029-06-05","has_results":false,"results_due":false,"sponsor_name":"Boehringer Ingelheim","sponsor_slug":"boehringer-ingelheim","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07629440","publication_url":"https://clinicaltrials.gov/study/NCT07629440","title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS","has_exemption":false,"start_date":"2026-05-29","completion_date":"2029-06-05","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07595042","publication_url":"https://clinicaltrials.gov/study/NCT07595042","title":"A Phase 2C Trial of Stratified Patient-Centered Treatment Regimens for Active TB","has_exemption":false,"start_date":"2026-10-30","completion_date":"2029-06-05","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06868290","publication_url":"https://clinicaltrials.gov/study/NCT06868290","title":"A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Active Granulomatosis With Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)","has_exemption":false,"start_date":"2025-03-13","completion_date":"2029-06-07","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218510","publication_url":"https://clinicaltrials.gov/study/NCT07218510","title":"A Phase 2 Study of Venetoclax + Obinutuzumab Followed by Epcoritamab in Previously Untreated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (LonGEVity)","has_exemption":false,"start_date":"2026-01-07","completion_date":"2029-06-08","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06564038","publication_url":"https://clinicaltrials.gov/study/NCT06564038","title":"A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies","has_exemption":false,"start_date":"2025-01-30","completion_date":"2029-06-11","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07772921","publication_url":"https://clinicaltrials.gov/study/NCT07772921","title":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF TILREKIMIG IN ADULT AND ADOLESCENT PARTICIPANTS WITH SEVERE ASTHMA","has_exemption":false,"start_date":"2026-08-24","completion_date":"2029-06-12","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06727773","publication_url":"https://clinicaltrials.gov/study/NCT06727773","title":"Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer","has_exemption":false,"start_date":"2025-08-19","completion_date":"2029-06-15","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07748208","publication_url":"https://clinicaltrials.gov/study/NCT07748208","title":"A Phase II Prospective, Open-Label Safety Study of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes","has_exemption":false,"start_date":"2026-09-01","completion_date":"2029-06-15","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07623200","publication_url":"https://clinicaltrials.gov/study/NCT07623200","title":"A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)","has_exemption":false,"start_date":"2026-09-08","completion_date":"2029-06-15","has_results":false,"results_due":false,"sponsor_name":"Incyte Corporation","sponsor_slug":"incyte-corporation","status":"ongoing","is_pact":false,"days_late":null}]}